Modern cold calling for startups under 20 people for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install modern cold calling has to reflect that reality from day one.

The under-20-person version of modern cold calling is not a diluted enterprise playbook. It is using the phone as a precision tool, not a volume weapon with different constraints: no headcount, no politics, and no time to be wrong for long.

Own it personally as a founder or lean-in operator for the first quarter. Hiring a specialist too early replaces context with process.

Pick one channel, one trigger, one message. Two of anything at this stage is too many and none of them will work.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Modern cold calling is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Instrument connects per hour on ICP dials in a spreadsheet if you have to. Legibility beats sophistication under 20 people.

The startup-specific trap is power dialers that torch the list in a week, usually because a well-meaning advisor points at what worked at their $50m company. Ignore.

Budget rules: whatever you spend on tools, spend the same on the person operating them. Under-tooling is fine; under-humaning is not.

A working modern cold calling function at 15 people is a genuine moat — most competitors of that size do not have one, and the discipline carries forward as the company grows.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing modern cold calling properly rather than half-heartedly across three vendors.